Neuroleptic Malignant Syndrome
Top Cited Papers
- 1 January 2011
- journal article
- Published by SAGE Publications in The Neurohospitalist
- Vol. 1 (1), 41-47
- https://doi.org/10.1177/1941875210386491
Abstract
Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic drugs characterized by fever, altered mental status, muscle rigidity, and autonomic dysfunction. It has been associated with virtually all neuroleptics, including newer atypical antipsychotics, as well as a variety of other medications that affect central dopaminergic neurotransmission. Although uncommon, NMS remains a critical consideration in the differential diagnosis of patients presenting with fever and mental status changes because it requires prompt recognition to prevent significant morbidity and death. Treatment includes immediately stopping the offending agent and implementing supportive measures, as well as pharmacological interventions in more severe cases. Maintaining vigilant awareness of the clinical features of NMS to diagnose and treat the disorder early, however, remains the most important strategy by which physicians can keep mortality rates low and improve patient outcomes.Keywords
This publication has 75 references indexed in Scilit:
- MOVEMENT DISORDERS ASSOCIATED WITH ARIPIPRAZOLE USE: A CASE SERIESInternational Journal of Neuroscience, 2009
- Atypical Neuroleptic Malignant Syndrome With QuetiapineJournal of Clinical Psychopharmacology, 2009
- Maligne Hyperthermie und deren DifferenzialdiagnosenFortschritte der Neurologie · Psychiatrie, 2009
- Olanzapine: review of safety 2008Expert Opinion on Drug Safety, 2008
- Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatmentThe World Journal of Biological Psychiatry, 2007
- Severe and Uncommon Involuntary Movement Disorders due to Psychotropic DrugsPharmacopsychiatry, 2004
- Is Neuroleptic Malignant Syndrome a Neurogenic Form of Malignant Hyperthermia?Clinical Neuropharmacology, 2002
- Electroconvulsive Treatment of Neuroleptic Malignant Syndrome: A Review and Report of CasesAustralian & New Zealand Journal of Psychiatry, 1999
- Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndromeJournal of Psychiatric Research, 1995
- A rapidly progressing lethal case of neuroleptic malignant syndromeIntensive Care Medicine, 1990